

## IP IRINOTECAN / CETUXIMAB / VEMURAFENIB (EVERY 14 DAYS)

Types: ONCOLOGY TREATMENT

Synonyms: BRAF, V600E, IRINOTECAN, IRIN, CAMPTOSAR, CAMP, CET, CETUXIMAB, VEMURAFENIB, ZELBORAF, VIC, COLORECTAL, GI

| Cycle 1   | Repeat 1 time | Cycle length: 14 days |
|---|---------------|-----------------------|
| <b>Day 1</b> Perform every 1 day x1   |               |                       |
| Provider Communication  |               |                       |
| <b>ONC PROVIDER COMMUNICATION</b><br>Interval: Once Occurrences: --<br>Comments: Presence of V600 mutation of BRAF gene must be documented by a CLIA-approved laboratory prior to initiation of Vemurafenib therapy.  |               |                       |
| Chemotherapy  |               |                       |
| <b>ONC NURSING COMMUNICATION 2</b><br>Interval: Once Occurrences: --<br>Comments: Patient to take home medication of Vemurafenib 960 mg by mouth twice daily on days 1 to 14 of treatment.  |               |                       |
| Provider Communication  |               |                       |
| <b>ONC PROVIDER COMMUNICATION 2</b><br>Interval: Once Occurrences: --<br>Comments: Tumor KRAS gene status should be determined prior to initiation of therapy. KRAS type: Please Push F2:115540219.   |               |                       |
| Labs  |               |                       |
| <input checked="" type="checkbox"/> <b>COMPREHENSIVE METABOLIC PANEL</b><br>Interval: Once Occurrences: --  |               |                       |
| <input checked="" type="checkbox"/> <b>CBC WITH PLATELET AND DIFFERENTIAL</b><br>Interval: Once Occurrences: --   |               |                       |
| <input checked="" type="checkbox"/> <b>MAGNESIUM LEVEL</b><br>Interval: Once Occurrences: --  |               |                       |
| Nursing Orders  |               |                       |
| <b>TREATMENT CONDITIONS 4</b><br>Interval: Until discontinued Occurrences: --<br>Comments: HOLD and notify provider if ANC LESS than 1000; Platelets LESS than 100,000; Total Bilirubin GREATER than 1.5; ALT/AST GREATER than 3 times upper normal limit; or Serum Creatinine GREATER than 1.2 |               |                       |
| Line Flush  |               |                       |
| <b>sodium chloride 0.9 % flush 20 mL</b><br>Dose: 20 mL Route: intravenous PRN<br>Start: S  |               |                       |
| Nursing Orders  |               |                       |
| <b>sodium chloride 0.9 % infusion 250 mL</b><br>Dose: 250 mL Route: intravenous once @ 30 mL/hr for 1 dose<br>Start: S<br>Instructions: To keep vein open.  |               |                       |
| Pre-Medications   |               |                       |



Dose: 500 mg/m<sup>2</sup>      Route: intravenous      once over 120 Minutes for 1 dose  
Offset: 30 Minutes

**Instructions:**

Administer with low protein binding 0.22 micron filter. Do not shake. Do not mix with other medications. Flush IV line with NS at the end of infusion.

1st infusion: Infuse first 10 mL over 10 minutes and observe patient for 30 minutes for allergic reactions if infusion tolerated, infuse loading dose over 120 minutes.

Rate of infusion not to exceed 10 mg/minute (5 mL/minute)

| <b>Ingredients:</b> | <b>Name</b>                                 | <b>Type</b> | <b>Dose</b>           | <b>Selected</b> | <b>Adds Vol.</b> |
|---------------------|---|-------------|-----------------------|-----------------|------------------|
|                     | CETUXIMAB 100 MG/50 ML INTRAVENOUS SOLUTION | Medications | 500 mg/m <sup>2</sup> | Main Ingredient | Yes              |

**Chemotherapy**

**irinotecan (CAMPTOSAR) 180 mg/m<sup>2</sup> in dextrose 5% 500 mL chemo IVPB**

Dose: 180 mg/m<sup>2</sup>      Route: intravenous      once over 90 Minutes for 1 dose  
Offset: 2.5 Hours

**Instructions:**

Protect from light

| <b>Ingredients:</b> | <b>Name</b>                                      | <b>Type</b> | <b>Dose</b>           | <b>Selected</b> | <b>Adds Vol.</b> |
|---------------------|--|-------------|-----------------------|-----------------|------------------|
|                     | IRINOTECAN 100 MG/5 ML INTRAVENOUS SOLUTION      | Medications | 180 mg/m <sup>2</sup> | Main Ingredient | Yes              |
|                     | DEXTROSE 5 % IN WATER (D5W) INTRAVENOUS SOLUTION | QS Base     | 500 mL                | Yes             | Yes              |
|                     | SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION       | QS Base     | 500 mL                | No              | Yes              |

**Hematology & Oncology Hypersensitivity Reaction Standing Order**

**ONC NURSING COMMUNICATION 82**

Interval: Until discontinued

Occurrences: --

**Comments:**

- Grade 1 - MILD Symptoms (cutaneous and subcutaneous symptoms only – itching, flushing, periorbital edema, rash, or runny nose)
1. Stop the infusion.
  2. Place the patient on continuous monitoring.
  3. Obtain vital signs.
  4. Administer Normal Saline at 50 mL per hour using a new bag and new intravenous tubing.
  5. If greater than or equal to 30 minutes since the last dose of Diphenhydramine, administer Diphenhydramine 25 mg intravenous once.
  6. If less than 30 minutes since the last dose of Diphenhydramine, administer Fexofenadine 180 mg orally and Famotidine 20 mg intravenous once.
  7. Notify the treating physician.
  8. If no improvement after 15 minutes, advance level of care to Grade 2 (Moderate) or Grade 3 (Severe).
  9. Assess vital signs every 15 minutes until resolution of symptoms or

otherwise ordered by covering physician.

### **ONC NURSING COMMUNICATION 83**

Interval: Until discontinued  
Comments:

Occurrences: --

Grade 2 – MODERATE Symptoms (cardiovascular, respiratory, or gastrointestinal symptoms – shortness of breath, wheezing, nausea, vomiting, dizziness, diaphoresis, throat or chest tightness, abdominal or back pain)

1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O<sub>2</sub> saturation of greater than or equal to 92%.
6. Administer Normal Saline at 150 mL per hour using a new bag and new intravenous tubing.
7. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous), Fexofenadine 180 mg orally and Famotidine 20 mg intravenous once.
8. If no improvement after 15 minutes, advance level of care to Grade 3 (Severe).
9. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.

### **ONC NURSING COMMUNICATION 4**

Interval: Until discontinued  
Comments:

Occurrences: --

Grade 3 – SEVERE Symptoms (hypoxia, hypotension, or neurologic compromise – cyanosis or O<sub>2</sub> saturation less than 92%, hypotension with systolic blood pressure less than 90 mmHg, confusion, collapse, loss of consciousness, or incontinence)

1. Stop the infusion.
2. Notify the CERT team and treating physician immediately.
3. Place the patient on continuous monitoring.
4. Obtain vital signs.
5. If heart rate is less than 50 or greater than 120, or blood pressure is less than 90/50 mmHg, place patient in reclined or flattened position.
6. Administer Oxygen at 2 L per minute via nasal cannula. Titrate to maintain O<sub>2</sub> saturation of greater than or equal to 92%.
7. Administer Normal Saline at 1000 mL intravenous bolus using a new bag and new intravenous tubing.
8. Administer Hydrocortisone 100 mg intravenous (if patient has allergy to Hydrocortisone, please administer Dexamethasone 4 mg intravenous) and Famotidine 20 mg intravenous once.
9. Administer Epinephrine (1:1000) 0.3 mg subcutaneous.
10. Assess vital signs every 15 minutes until resolution of symptoms or otherwise ordered by covering physician.

### **diphenhydrAMINE (BENADRYL) injection 25 mg**

Dose: 25 mg                      Route: intravenous                      PRN  
Start: S

### **fexofenadine (ALLEGRA) tablet 180 mg**

Dose: 180 mg                      Route: oral                      PRN  
Start: S

**famotidine (PEPCID) 20 mg/2 mL injection 20 mg**

Dose: 20 mg                      Route: intravenous              PRN  
Start: S

**hydrocortisone sodium succinate (Solu-CORTEF) injection 100 mg**

Dose: 100 mg                      Route: intravenous              PRN

**dexamethasone (DECADRON) injection 4 mg**

Dose: 4 mg                      Route: intravenous              PRN  
Start: S

**epINEPHrine (ADRENALIN) 1 mg/10 mL ADULT injection syringe 0.3 mg**

Dose: 0.3 mg                      Route: subcutaneous              PRN  
Start: S

**Nursing Orders**

**ONC NURSING COMMUNICATION 14**

Interval: Until                      Occurrences: --  
discontinued

Comments:                      Contact Provider if drug-induced acneiform rash develops and covers more than 25 per cent of the body.

**Discharge Nursing Orders**

**sodium chloride 0.9 % flush 20 mL**

Dose: 20 mL                      Route: intravenous              PRN

**HEParin, porcine (PF) injection 500 Units**

Dose: 500 Units                      Route: intra-catheter              once PRN  
Start: S

Instructions:

Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.